A morphologic variant of small cell lung carcinoma in combination with a non-small cell carcinoma.
Comprehensive, easy-to-understand information about this condition
How we create this content →The limited documentation surrounding combined small cell lung carcinoma is largely due to its rarity and the complexity of its clinical features, which often overlap with other lung cancer types. As this condition affects a small number of individuals, comprehensive clinical studies have been sparse, making it challenging to gather systematic data and insights.
To navigate your care, consider seeking a medical oncologist with specialized experience in lung cancers, particularly those that include small cell variants. Engaging with clinical trial coordinators can provide access to cutting-edge treatments. You may also want to explore resources like the National Organization for Rare Disorders (NORD) at rarediseases.org for additional support and information. Participating in clinical trials may also provide valuable insights into your condition and potential treatment options.
There are several orphan drugs designated for combined small cell lung carcinoma, including atezolizumab, lurbinectedin, and tarlatamab-dlle. Additionally, there are 840 active clinical trials investigating various treatment options. You can explore these trials further at ClinicalTrials.gov using the following link: https://clinicaltrials.gov/search?cond=combined%20small%20cell%20lung%20carcinoma.
Actionable guidance for navigating care for combined small cell lung carcinoma
To navigate your care, consider seeking a medical oncologist with specialized experience in lung cancers, particularly those that include small cell variants. Engaging with clinical trial coordinators can provide access to cutting-edge treatments. You may also want to explore resources like the National Organization for Rare Disorders (NORD) at rarediseases.org for additional support and information. Participating in clinical trials may also provide valuable insights into your condition and potential treatment options.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The limited documentation surrounding combined small cell lung carcinoma is largely due to its rarity and the complexity of its clinical features, which often overlap with other lung cancer types. As this condition affects a small number of individuals, comprehensive clinical studies have been sparse, making it challenging to gather systematic data and insights.
To navigate your care, consider seeking a medical oncologist with specialized experience in lung cancers, particularly those that include small cell variants. Engaging with clinical trial coordinators can provide access to cutting-edge treatments. You may also want to explore resources like the National Organization for Rare Disorders (NORD) at rarediseases.org for additional support and information. Participating in clinical trials may also provide valuable insights into your condition and potential treatment options.
There are several orphan drugs designated for combined small cell lung carcinoma, including atezolizumab, lurbinectedin, and tarlatamab-dlle. Additionally, there are 840 active clinical trials investigating various treatment options. You can explore these trials further at ClinicalTrials.gov using the following link: https://clinicaltrials.gov/search?cond=combined%20small%20cell%20lung%20carcinoma.
Actionable guidance for navigating care for combined small cell lung carcinoma
To navigate your care, consider seeking a medical oncologist with specialized experience in lung cancers, particularly those that include small cell variants. Engaging with clinical trial coordinators can provide access to cutting-edge treatments. You may also want to explore resources like the National Organization for Rare Disorders (NORD) at rarediseases.org for additional support and information. Participating in clinical trials may also provide valuable insights into your condition and potential treatment options.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The limited documentation surrounding combined small cell lung carcinoma is largely due to its rarity and the complexity of its clinical features, which often overlap with other lung cancer types. As this condition affects a small number of individuals, comprehensive clinical studies have been sparse, making it challenging to gather systematic data and insights.
To navigate your care, consider seeking a medical oncologist with specialized experience in lung cancers, particularly those that include small cell variants. Engaging with clinical trial coordinators can provide access to cutting-edge treatments. You may also want to explore resources like the National Organization for Rare Disorders (NORD) at rarediseases.org for additional support and information. Participating in clinical trials may also provide valuable insights into your condition and potential treatment options.
There are several orphan drugs designated for combined small cell lung carcinoma, including atezolizumab, lurbinectedin, and tarlatamab-dlle. Additionally, there are 840 active clinical trials investigating various treatment options. You can explore these trials further at ClinicalTrials.gov using the following link: https://clinicaltrials.gov/search?cond=combined%20small%20cell%20lung%20carcinoma.
Actionable guidance for navigating care for combined small cell lung carcinoma
To navigate your care, consider seeking a medical oncologist with specialized experience in lung cancers, particularly those that include small cell variants. Engaging with clinical trial coordinators can provide access to cutting-edge treatments. You may also want to explore resources like the National Organization for Rare Disorders (NORD) at rarediseases.org for additional support and information. Participating in clinical trials may also provide valuable insights into your condition and potential treatment options.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Consider asking your healthcare providers these condition-specific questions
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
No approved therapies yet
Research is ongoing — 11 companies have orphan drug designations for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.